Skip to main content
. 2014 Jan 2;18(3):271–280. doi: 10.1016/j.bjid.2013.07.011

Table 2.

EBV viral load measure in different virus persistence sites.

Study groups N Median of normalized EBV load (range) CIa
Lymphoid tissue
(EBV gEq/105 cells)		 Peripheral blood mononuclear cells
(EBV gEq/105 cells)		 Plasma (EBV gEq/mL)
Blood donors 66 – <3
100%: <100		 <100
100%: <100
Non-transplanted patients with LH 64 4 (<3–822)
95.7%: 3–12		 <10 (<3–124.1)
95.6%: <10		 <100
100%: <100
Transplant patients without PTLD 47 133.5 (<3–9786)
96.9%: 3–479		 11.5 (<3–432.6)
96.6: <3–16		 <100 (<100–3107)
97.2%: <100
Transplant patients with PTLD 54 239 (3–1,775,353)
95.6%: 52–373		 21.5 (<3–32,181)
96.7%: 8–37		 <100 (<100–23,997)
95.6%: <100

PTLD, post-transplant lymphoproliferative disorders; CI, confidence interval; EBV gEq, EBV genome equivalents; LH, lymphoid hypertrophy.